Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment

Reuters11-04

<a href="https://laohu8.com/S/IMMX">Immix Biopharma</a> Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment

Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580724727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580724727","market":"fut","top_or_hot":-1,"title":"Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 04:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL3Sq0SC:1","article_id":"2580724727","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580724727","pubTimestamp":1762202555,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMMX":"Immix Biopharma, Inc"},"translate_title":"Immix Biopharma推出治疗复发性AL淀粉样变性的突破性方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment\n    \n\n        Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580724727","isCrawlerRequest":true}